On January 6, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually (Press release, Infinity Pharmaceuticals, JAN 6, 2022, View Source [SID1234598326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference details can be found below:

J.P. Morgan Healthcare Conference 2022
Format: Corporate presentation and 1-on-1 meetings
Date and Time: Presentation at 7:30am ET January 13, 2022
Presentation Link
The presentation and archived webcast can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.